Innatebiome & Verzanobio
Biotechnology, 6650 Lusk BLVD, San Diego, California, 92121, United States, 1-10 Employees
Who is INNATEBIOME & VERZANOBIO
DevaCell is rapidly advancing a pipeline of therapeutic product candidates based on a proprietary synthetic vector engineering platform technology. Key therapeutic segments include - onco...
Read More
-
Headquarters: 6650 Lusk BLVD, San Diego, California, 92121, United States
-
Date Founded: 2015
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
-
CEO:
David Pyrce
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from INNATEBIOME & VERZANOBIO
Innatebiome & Verzanobio Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Innatebiome & Verzanobio
Answer: Innatebiome & Verzanobio's headquarters are located at 6650 Lusk BLVD, San Diego, California, 92121, United States
Answer: Innatebiome & Verzanobio's official website is https://devacell.com
Answer: Innatebiome & Verzanobio's revenue is Under $1 Million
Answer: Innatebiome & Verzanobio's SIC: 2834
Answer: Innatebiome & Verzanobio's NAICS: 325412
Answer: Innatebiome & Verzanobio has 1-10 employees
Answer: Innatebiome & Verzanobio is in Biotechnology
Answer: Innatebiome & Verzanobio contact info: Phone number: Website: https://devacell.com
Answer: DevaCell is rapidly advancing a pipeline of therapeutic product candidates based on a proprietary synthetic vector engineering platform technology. Key therapeutic segments include - oncolytic cancer immunotherapy, gene therapy/gene editing and vaccines. Based on the transformative and proprietary ONCoat, nanoparticle-based synthetic vector platform technology, the company's lead therapeutic program is a synthetic vector based oncolytic cancer immunotherapy with multiple transgene payloads encoded into an engineered, adenovirus (Ad5) backbone, targeting solid tumors. The program is currently transitioning to IND-enabling studies, with human clinical trials anticipated to launch by year-end 2021. In the infectious disease segment, advancing to IND-enabling studies is an COVID-19 vaccine based on the same Ad5 backbone, engineered to express the SARSCoV19 virus spike protein. The company's gene therapy/gene editing program is currently in discovery research with product candidates anticipated to advance to IND-enabling studies in the second half of 2021.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month